L. Volpi
University of Siena
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by L. Volpi.
European Journal of Clinical Pharmacology | 1991
T. Di Perri; Franco Laghi Pasini; C. Frigerio; Patrizia Blardi; F. Centini; G.L. Messa; A. Ghezzi; L. Volpi
SummaryIn 6 normal volunteers given single oral doses of 250, 500 and 1000 mg ticlopidine (T), the peak plasma level of unchanged drug was reached after about 2 h. There was no correlation between the plasma T level and its inhibitory effect on platelet function, expressed as % inhibition of ADP-induced aggregation. By means of HPLC and GC/MS significant concentrations of T were demonstrated in washed red cells, platelets and neutrophils, with a marked difference in the time course of the appearance of cell-associated drug. The time course of platelet-associated T very accurately fitted that of the antiaggregatory activity.After subacute oral administration (250 mg b. d. for 7 days), the maximum effect on platelet function was observed after 3 to 4 days, when a significant concentration of platelet-associated T had been reached. The pharmacological effect persisted as long as drug was detectable in platelet.An in vitro study strongly suggested that the antiaggregating effect was retained by treated washed platelets but not by treated plasma. It is suggested that the platelet compartment represents the pharmacological target of T via a specific uptake system.
Clinical Pharmacology & Therapeutics | 2002
Patrizia Blardi; Renato Urso; Arianna De Lalla; L. Volpi; Tullio Di Perri; A. Auteri
Nimodipine is a dihydropyridine calcium channel blocker used in the treatment of ischemic damage in subarachnoid hemorrhage. Recent investigations have shown that it is able to inhibit adenosine transport in human red blood cells and parietal cortex neurons. In this study we investigated the pharmacokinetics of nimodipine and the effect on plasma adenosine levels in patients affected by cerebral ischemia.
European Journal of Clinical Pharmacology | 1993
Patrizia Blardi; F. Laghi Pasini; Renato Urso; C. Frigerio; L. Volpi; L. De Giorgi; T. Di Perri
SummaryThe plasma kinetics of adenosine was investigated in healthy volunteers after a 1 minute infusion of 2.5, 5 and 10 mg (38, 79 and 148 μg·kg−1 respectively) and after infusion of 200 μg·kg−1 in 10 min followed by 400 μg·kg−1 in 10 min.As the dose in the 1 min infusion study was increased the mean CL of adenosine decreased (10.7, 4.70 and 4.14 l·min−1, respectively), its mean half-life increased (0.91, 1.24 and 1.86 min, respectively), and the mean volume of distribution did not show any clear trend (8–13 l).After the 20 minute infusion the plasma level of adenosine reached a peak value comparable to that observed after infusion of 5 mg in 1 min (about 0.5 μg·ml−1), but the mean clearance and half-life were significantly different (12.1 l·min−1 and 0.63 min respectively).In all the subjects the plasma concentration of adenosine had returned to the baseline value in 5–15 min after the end of the infusion.
Clinical Pharmacology & Therapeutics | 1995
Pier Leopoldo Capecchi; Patrizia Blardi; Arianna De Lalla; L. Ceccatelli; L. Volpi; Franco Laghi Pasini; Tullio Di Perri
To study the possibility that the penetration of the antibiotic ciprofloxacin into polymorphonuclear leukocytes (PMN) may be associated with some changes in cell reactivity.
European Journal of Clinical Pharmacology | 1992
T. Di Perri; F. Laghi Pasini; Capecchi Pl; Patrizia Blardi; Anna Laura Pasqui; M. Franchi; S. Mazza; N. Sodi; L. Domini; L. Ceccatelli; L. Volpi
SummaryIn order to define the pharmacodynamic profile of salmon calcitonin (sCT) in humans, several markers of the biological activity of the drug have been studied, namely cAMP, adenosine and pO2 in venous blood, and the cytosolic free calcium level in circulating cells. Different dosages and routes of administration (1.5 IU. kg−1 and 0.75 IU kg−1 IM, and 1.5 IU. kg−1 via nasal spray) were compared.sCT caused an increase in cAMP, adenosine and pO2, and a decrease in cytosolic free calcium in neutrophils, lymphocytes and platelets. The peak times of all these parameters ranged between 109 and 182 min, and 101 and 168 min after IM and nasal spray administration respectively. There was greater variability in the values after IM than nasal spray of administration of sCT.It is concluded that adenosine and p02 in venous blood, and cytosolic free calcium in circulating cells are valuable markers of the activity of sCT and that sCT decreases the cytosolic free calcium level in neutrophils, lymphocytes and platelets. Pharmacodynamic analysis of the biological effects of the drug is highly reliable and valuable in predicting its pharmacological profile. sCT administration via a nasal spray is able to produce significant biological effects, although they are less marked than after IM dosing.
Clinical and Experimental Pharmacology and Physiology | 1995
Franco Laghi Pasini; C. Frigerio; Patrizia Blardi; Lorenzo Domini; Laura De Giorgi; Giovanna Borgogni; S. Pecchi; Graziella Cati; M. Franchi; L. Volpi; Tullio Di Perri
1. The hypothesis that endogenous adenosine could play a role in the haemodynamic response to l‐arginine is investigated.
European Journal of Clinical Pharmacology | 1989
T. Di Perri; F. Laghi Pasini; C. Frigerio; Capecchi Pl; G.L. Messa; M. Franchi; F. Landini; A. Burresi; A. Ghezzi; L. Ceccatelli; L. Volpi; Patrizia Blardi
In the past few years there has been increasing interest in the role of the vascular endothelium as an active modulator of biological responses. Endothelial cells exert antithrombotic activity by the release of prostacyclin [23] and adenine nucleotides [16], the availability on the cell surface of heparin-like substances [3], and thrombomodulin-mediated activation of protein C [8]. In addition, endothelium is involved in the regulation of fibrinolysis by releasing soluble factors, such as tissue plasminogen activator (tPA; [10]) and plasminogen activator inhibitor (PAI; [22, 11]), as well as in the control of vascular responsiveness by the production of smooth muscle relaxing and contracting factors. Endothelial cells have also been shown to synthesize and to express procoagulant activities [18].Many data on endothelial cell functions has been obtained from two experimental models, namely endothelial cell cultures and perfused segments of animal and human vessels. Both are subject to methodological criticism since they only represent in part in vivo conditions, and the necessary experimental manipulations and laboratory procedures greatly modify the naturally occurring cellular functions.In order to overcome such difficulties as far as possible, a new in vivo model has been employed to provide easily assessable and reliable data on the properties of endothelial cells in man. A venous segment was isolated functionally by cannulating a dorsal vein in the hand and a cubital vein in the same arm. Changes observed ex vivo in blood from the cubital vein following infusion into the hand vein of an active drug, can mainly be attributed to its local effect on the venous wall. At the same time, a cubital vein in the other arm was cannulated in order to provide information to distinguish systemic from regional effects.
Journal of International Medical Research | 1990
Sandro Forconi; Roberto Cappelli; M. Guerrini; L. Volpi; C. Frigerio; T. Di Perri
Cyclandelate, a vasoactive substance consisting of the mandelic acid ester of 3,3,5-trimethylcyclohexanol, was administered to 10 patients with cerebrovascular and/or peripheral vascular disease. Blood specimens were collected at 1 − 6 h after oral administration of 1600 mg cyclandelate, and the ester and acid were extracted from plasma in acid medium using n-hexane/isopropyl alcohol. The concentrations were determined by a high-performance liquid chromatography isocratic system. The highest plasma cyclandelate concentrations were detected at the third hour, whereas plasma mandelic acid concentrations were still increasing 6 h after administration.
Drugs Under Experimental and Clinical Research | 1999
Patrizia Blardi; L. A. De; L. Volpi; T. Di Perri
Clinical Hemorheology and Microcirculation | 2018
T. Di Perri; F. Laghi Pasini; L. Ralli; S. Pecchi; V. De Franco; P. Damiani; L. Domini; M. Materazzi; A. Monaci; M. Franchi; A. Burresi; F. Landini; D. Pieragalli; A. Acciavatti; C. Galigani; C. Frigerio; G.L. Messa; Patrizia Blardi; L. Volpi